Calibr, a division of Scripps Research
11
3
3
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
27.3%
3 terminated/withdrawn out of 11 trials
57.1%
-29.4% vs industry average
0%
0 trials in Phase 3/4
50%
2 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Long Term Follow-up Study for Subjects Administered CLBR001
Role: lead
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Role: lead
A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases
Role: lead
CLF065 for Chronic Pouchitis
Role: lead
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer
Role: lead
Study to Assess PDM608 in Healthy Adult Subjects
Role: lead
Study to Assess CMR316 in Healthy Volunteers and Patients With Idiopathic Pulmonary Fibrosis
Role: lead
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
Role: lead
First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer
Role: lead
A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of KA34 in Subjects With Knee Osteoarthritis
Role: lead
A Phase 2A Evaluation of the Safety, Tolerability, Pharmacokinetics, Efficacy of Clofazimine (CFZ) in Cryptosporidiosis
Role: collaborator
All 11 trials loaded